The shared HLA-bound neoepitopes in pancreatic ductal adenocarcinoma (PDAC) represent a novel class of non-canonical antigens with single amino acid substitutions, resulting from translational errors. These peptides, shared across PDAC patients, showed higher immunogenicity than wild-type counterparts, offering potential candidates for specific immunotherapy development in PDAC.